Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Mental and physical health links a global issue
Wed July 17th - Action is needed on the physical health inequalities faced by people with mental illness, according to a major global study published today. More
Mixed findings for iron status
Wed July 17th - New research has found a mixture of positive and negative effects of having naturally higher iron levels. More
Regeneration device tested for myocardiopathy
Wed July 17th - A patient has successfully been implanted with a new microcurrent generator, developed to stimulate recovery from myocardiopathy, Austrian doctors have announced. More
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
guide to breast disorders guide to womb disorders guide to menopause Complete Women's Health: from The Royal College of Obstetricians and Gynaecologists For books and family gift ideas click here
RSS graphic XML Graphic

Call to personalise de-escalation treatment for HER2 positive breast cancer

Thursday May 2nd, 2019

The decision to remove chemotherapy from treatment for women with HER2 positive breast cancer must be done on a personalised basis to identify which patients would benefit the most, a European conference has heard.

Delegates at the ESMO Breast Cancer Congress 2019, in Berlin, Germany, heard yesterday that the PERNETTA trial found that de-escalation in the first line treatment of HER2 positive metastatic breast cancer did not worsen two-year overall survival but significantly shortened progression-free survival.

It is why, said Dr Carmen Criscitiello, European Institute of Oncology, Milan, Italy, that personalised treatment is necessary.

"The introduction of anti-HER2 therapies has brought a huge survival benefit in early and advanced HER2 positive breast cancer, thus there is now a need for reducing the intensity and side effects of the treatment administered," she said.

"However, the priority is to identify which patients might be spared some toxic therapies without worsening the survival benefit."

The phase II trial involved 210 patients, who were randomly allocated either trastuzumab plus pertuzumab alone or trastuzumab plus pertuzumab combined with chemotherapy. Following progression, both groups received T-DM1 as second line therapy.

The researchers found that progression-free survival after first line therapy was 8.4 months with antibodies alone and 23.3 months with antibodies plus chemotherapy group.

At the conference, delegates were told that the results were similar regardless of hormone receptor status, and overall quality of life was also similar between groups during first line treatment.

The difference in progression-free survival between groups led the research team to look for predictive factors to identify patients who could receive targeted therapy alone with little or no detriment in progression-free survival. They used the PAM50 test to profile tumours of all patients in the trial.

Dr Criscitiello said it is important for studies in this field to select a specific population in which to attempt treatment intensity optimisation, admitting that using the PAM50 test to select patients with the HER2 enrichment subtype may be an effective approach.

"There was no biological selection of patients in the PERNETTA trial," she said. “Here we have a progression-free survival that is almost two times less than that achieved with chemotherapy. The short overall survival endpoint did not capture if denying a treatment, which is demonstrated to be meaningfully most effective, impacts on long-term survival. In addition, the sample size is very small to detect a difference in overall survival.

“Avoiding chemotherapy in HER2 positive disease is appealing for patients and investigators, but it has to be done safely."

Tags: Cancer | Europe | Women's Health & Gynaecology

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)